Wuhan Hiteck Biological Pharma Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Wuhan Haite Biopharmaceutical Co., Ltd. is a high-tech biopharmaceutical enterprise with the goal of building an excellent innovative biopharmaceutical enterprise in China. It was listed on the Growth Enterprise Board of the Shenzhen Stock Exchange on August 8, 2017 (stock abbreviation: Haite Biotech, stock code: 300683). Our main business is the production and sales of bioengineering products and freeze-dried powder injections; The import and export business of our company's products and technologies. At present, the company has 25 production numbers for biological products and chemical drugs. The company's park covers an area of 138000 square meters, with an existing building area of over 61000 square meters. It has a production plant that meets national GMP standards of over 14800 square meters, complete facilities, and equipment flow. As well as the corresponding drug quality management system, a fully functional quality management department has been established to strictly follow GMP requirements for drug production and comprehensive quality management, in order to achieve the company's quality policy and optimize product quality. And has established project cooperation relationships with several famous academicians. The company has established a core cultural system, working together with its employees to develop and cultivate high-quality management talents and engineering technicians who are "honest, grateful, professional, and enterprising". The company is a high-tech enterprise in Hubei Province. There are postdoctoral mobile workstations approved by the Ministry of Human Resources and Social Security of the People's Republic of China, as well as the "Hubei Rare Disease Drug Engineering Technology Research Center" and "Hubei High tech Innovation Enterprise" approved by the provincial science and technology department, which have established five basic technology work platforms, promoted the industrialization of related achievements, and efficiently transformed pilot bases into the market. The company is based on the research and development and production of drugs in the fields of nervous system and oncology. At present, a national Class I biological drug - injection mouse nerve growth factor NGF (Jinlujie) has been launched and sold, and a Class I genetic engineering biological drug - recombinant mutant human tumor necrosis factor related apoptosis inducing ligand project (CircularPermutedTRAIL, abbreviated as CPT) has completed phase III clinical unblinding work and is in the preparation stage for production approval. The company adheres to the corporate philosophy of "respecting life and fearless innovation", practices the corporate values of "integrity, gratitude, professionalism, and progress", and strives to build Haite Biological into a top innovative pharmaceutical enterprise in China. The company will expand in the fields of macromolecular drugs, small molecule drugs, in vitro diagnosis, etc., with serving patients as its responsibility and continuous innovation as the leader, to build Haite Biological into a pharmaceutical enterprise group!. |
| Headquarter | Wuhan |
| Establish Date | 4/8/1992 |
| Listed Code | 300683.SZ |
| Listed Date | 8/8/2017 |
| Chairman | Chen Ya. |
| CEO | Chen Ya. |
| Website | www.hiteck.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
